Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO	$0.71 +2.5%	$0.87	$0.66 ▼ $3.84	$31.24M	1.35	880,508 shs	305,500 shs
PRQR ProQR Therapeutics	$2.16	$1.70	$1.07 ▼ $4.62	$227.26M	0.31	649,418 shs	536,165 shs
RAPT Rapt Therapeutics	$9.73 +1.8%	$7.62	$5.67 ▼ $30.60	$158.09M	-0.11	162,738 shs	119,320 shs
SGHT Sight Sciences	$4.25 +0.7%	$3.56	$2.03 ▼ $8.45	$218.16M	2.46	216,585 shs	67,027 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	0.00%
PRQR ProQR Therapeutics	0.00%	+11.34%	+27.06%	+54.29%	+30.91%
RAPT Rapt Therapeutics	+1.78%	+31.13%	+24.64%	-0.31%	-60.12%
SGHT Sight Sciences	+0.71%	-0.47%	+23.55%	+66.67%	-32.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEXO HEXO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	1.9634 of 5 stars	3.6	3.0	0.0	0.0	2.7	0.0	0.0
RAPT Rapt Therapeutics	3.8171 of 5 stars	3.2	1.0	0.0	4.2	1.8	1.7	1.3
SGHT Sight Sciences	1.4153 of 5 stars	1.1	4.0	0.0	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEXO HEXO	0.00	N/A	N/A	N/A
PRQR ProQR Therapeutics	3.13	Buy	$8.00	270.37% Upside
RAPT Rapt Therapeutics	2.33	Hold	$24.00	146.66% Upside
SGHT Sight Sciences	2.29	Hold	$4.10	-3.53% Downside

Current Analyst Ratings Breakdown

Latest HEXO, PRQR, SGHT, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	SGHT Sight Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.50 ➝ $4.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/22/2025	SGHT Sight Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.20 ➝ $3.60
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/9/2025	SGHT Sight Sciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$2.50 ➝ $3.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/9/2025	SGHT Sight Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEXO HEXO	$146.20M	0.21	N/A	N/A	$2.44 per share	0.29
PRQR ProQR Therapeutics	$20.46M	11.11	N/A	N/A	$0.91 per share	2.37
RAPT Rapt Therapeutics	$1.53M	105.19	N/A	N/A	$11.51 per share	0.85
SGHT Sight Sciences	$79.87M	2.75	N/A	N/A	$1.72 per share	2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEXO HEXO	-$845.90M	-$5.21	N/A	N/A	N/A	-235.33%	-74.04%	-32.51%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)
SGHT Sight Sciences	-$51.51M	-$0.98	N/A	N/A	N/A	-63.24%	-54.62%	-34.92%	7/30/2025 (Estimated)

Latest HEXO, PRQR, SGHT, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A
5/8/2025	Q1 2025	SGHT Sight Sciences	-$0.29	-$0.28	+$0.01	-$0.28	$16.51 million	$17.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
SGHT Sight Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEXO HEXO	0.01	0.41	0.24
PRQR ProQR Therapeutics	N/A	4.10	4.10
RAPT Rapt Therapeutics	N/A	21.11	21.11
SGHT Sight Sciences	0.51	10.47	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEXO HEXO	7.78%
PRQR ProQR Therapeutics	32.65%
RAPT Rapt Therapeutics	99.09%
SGHT Sight Sciences	55.51%

Insider Ownership

Company	Insider Ownership
HEXO HEXO	4.69%
PRQR ProQR Therapeutics	8.40%
RAPT Rapt Therapeutics	2.36%
SGHT Sight Sciences	30.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEXO HEXO	1,277	44.00 million	41.93 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable
SGHT Sight Sciences	210	51.70 million	35.72 million	Optionable

HEXO, PRQR, SGHT, and RAPT Headlines

Recent News About These Companies

Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.10 Consensus Target Price from Analysts

3 hours ago | americanbankingnews.com

Sight Sciences Leads The Pack Of 3 Promising Penny Stocks

June 24 at 3:49 PM | uk.finance.yahoo.com

Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by Brokerages

June 24 at 2:41 AM | marketbeat.com

Piper Sandler Raises Sight Sciences (NASDAQ:SGHT) Price Target to $4.00

June 18, 2025 | marketbeat.com

Millennium Management LLC Invests $464,000 in Sight Sciences, Inc. (NASDAQ:SGHT)

June 10, 2025 | marketbeat.com

sight sciences appoints new board member and holds annual meeting

June 7, 2025 | uk.investing.com

Squarepoint Ops LLC Buys 128,355 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

June 4, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of "Hold" from Analysts

May 31, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Shares Sold by Bank of America Corp DE

May 30, 2025 | marketbeat.com

BNP Paribas Financial Markets Invests $262,000 in Sight Sciences, Inc. (NASDAQ:SGHT)

May 30, 2025 | marketbeat.com

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

May 14, 2025 | globenewswire.com

Sight Sciences stock holds as Needham reiterates rating

May 11, 2025 | uk.investing.com

Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

May 10, 2025 | finance.yahoo.com

Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

May 8, 2025 | zacks.com

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Why Sight Sciences, Inc.’s (SGHT) Stock Is Down 5.02%

April 26, 2025 | aaii.comA

Sight Sciences appoints new board member

April 24, 2025 | investing.com

Sight Sciences, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEXO, PRQR, SGHT, and RAPT Company Descriptions

HEXO NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

ProQR Therapeutics NASDAQ:PRQR

$2.16 0.00 (0.00%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.14 -0.02 (-0.69%)

As of 06/26/2025 06:44 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Rapt Therapeutics NASDAQ:RAPT

$9.73 +0.17 (+1.78%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$9.68 -0.04 (-0.46%)

As of 06/26/2025 07:44 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Sight Sciences NASDAQ:SGHT

$4.25 +0.03 (+0.71%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.26 +0.00 (+0.12%)

As of 06/26/2025 04:04 PM Eastern

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time